BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

TapImmune Inc. 

2815 Eastlake Avenue East
Suite 300
Seattle  Washington  98102  U.S.A.
Phone: 866-359-7541 Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Oncology
Vaccines





 Company News
Published Review and Analyst Report Boost TapImmune Inc. (TPIV) Shares 11/20/2014 2:37:19 PM
VGTI Florida To Collaborate With TapImmune Inc. (TPIV) To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials 11/19/2014 12:06:31 PM
TapImmune Inc. (TPIV) Announces Phase 2 Clinical Trials Collaboration With VGTI Florida To Advance Breast And Ovarian Cancer Vaccines 11/18/2014 10:26:08 AM
TapImmune Inc. (TPIV) Provides Update On Polystart™ Vaccine Platform Applicable To Cancer And Infectious Disease 10/22/2014 7:41:11 AM
TapImmune Inc. (TPIV) CEO Provides Update On Corporate Activity And Progression Of Clinical Programs 9/23/2014 10:48:54 AM
TapImmune Inc. (TPIV) Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer 9/16/2014 8:55:22 AM
TapImmune Inc. (TPIV) Announces $2 Million Registered Direct Offering 8/11/2014 10:42:10 AM
TapImmune Inc. (TPIV)'s New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens 8/7/2014 11:08:05 AM
TapImmune Inc. (TPIV) Prevails In Legal Dispute With Michael Gardner 7/24/2014 10:53:30 AM
TapImmune Inc. (TPIV) Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board 6/13/2014 7:29:08 AM
12345678